The Philippines has launched an investigation into the immunisation of 730,000 kids with a dengue vaccine that would pose well being dangers.
Final week French drug firm Sanofi introduced their vaccine may worsen the doubtless lethal illness in individuals not beforehand contaminated.
The general public immunisation programme was suspended on Friday.
Dengue fever impacts greater than 400 million individuals a 12 months world wide.
The mosquito-borne illness is a number one trigger of great sickness and demise amongst kids in some Asian and Latin American international locations, according to the World Health Organisation.
Sanofi mentioned in a press convention on Monday that there had been no reported deaths associated to its dengue vaccine within the Philippines.
“So far as we all know, so far as we’re made conscious, there are not any reported deaths which are associated to dengue vaccination,” the corporate’s medical director Ruby Dizon instructed reporters on Monday.
“After all, relaxation assured, monitoring is continuous, we’re working with the Division of Well being (DOH), in collaboration, to verify that is maintained.”
Philippine Presidential Spokesperson Harry Roque on Monday mentioned that “individuals shouldn’t panic over the dengue vaccine” as the federal government was trying into the matter.
Sanofi’s Dengvaxia is the first-ever accepted Dengue vaccine, however the agency mentioned final week new long-term research confirmed that whereas it labored with individuals who had prior an infection, it posed a threat for many who hadn’t.
“For these not beforehand contaminated by dengue virus, nonetheless, the evaluation discovered that in the long run, extra instances of extreme illness may happen following vaccination upon a subsequent dengue an infection,” the company said in a statement.
The agency mentioned it could ask well being authorities to up to date the data given to docs and sufferers working with the vaccine.